In a historic milestone for oncology, the us food and drug administration (FDA) has granted expedited approval to Daraxonrasib (marketed as rasonque by revolution medicines), marking the first-ever approved targeted therapy to successfully tackle the "undruggable" ras protein mutations that drive over 90% of pancreatic cancers.  

New drug offers hope for advanced pancreatic cancer

In a historic milestone for oncology, the US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib (marketed as Rasonque by Revolution Medicines), marking the first-ever approved targeted therapy to successfully tackle the "undruggable" RAS protein mutations that drive over 90% of pancreatic cancers.  


FDA approves new pill that nearly doubles pancreatic cancer survival time

The Maharashtra Food and Drug Administration (FDA) has issued show-cause notices to Bollywood actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff over their advertisement for a pan masala brand. The regulator alleged that the campaign amounts to surrogate advertising for a product currently banned in the state.


Maharashtra FDA crackdown: Shah Rukh Khan & Ajay Devgn receive FDA notices

Karnataka's Food Safety and Drug Administration widened its statewide crackdown by raiding canteens right inside the seat of power, Vidhan Soudha and nearby government buildings. Inspectors found cockroaches crawling on food plates, expired items like idli rava and coconut powder, poor storage practices, and missing pest control at a restaurant inside the Legislators' House.


Karnataka FDA finds cockroaches and expired food in Vidhan Soudha canteen raid 

The Maharashtra Food and Drug Administration (FDA) has cracked down hard on the booming quick-commerce sector, suspending the food license of a Blinkit dark store in Malad West, Mumbai. Watch the full video to know more on this.


Maharashtra ramps up food safety raids across state 

Maharashtra FDA Commissioner Tukaram Mundhe speaks about the state’s food safety crackdown, stressing that public health, not individual credit, is the priority. From inspections and digital systems to consumer awareness, he explains why enforcement must be institutional, why ex-officials cannot shield violators, and why consumers must look beyond price and expiry dates. He also clarifies that not every food business is a violator.


FDA Commissioner Tukaram Mundhe highlights key food safety concerns on WION

Led by FDA Commissioner Tukaram Mundhe, the Maharashtra FDA has conducted more than 1,100 surprise inspections and raids across the state. The crackdown targeted unhygienic food practices, adulterated milk, fake paneer and unlicensed kitchens at hotels, restaurants and institutional canteens.

Maharashtra: New FDA chief Tukaram Mundhe conducts mass inspections

The Maharashtra FDA has introduced new guidelines aimed at restricting the sale of junk food near schools to promote healthier eating habits among students. The initiative seeks to reduce children's access to foods high in sugar, salt, and unhealthy fats while encouraging nutritious alternatives in and around educational institutions. The move is part of broader public health efforts to combat childhood obesity, improve nutrition, and create a healthier school environment across the state.

Maharashtra FDA launches new guidelines: Government to prohibit sale of junk food near schools

Mumbai: In one of Maharashtra's biggest food safety crackdowns targeting high-profile establishments, the state's Food and Drug Administration (FDA) has suspended the FSSAI food business licences of five of Mumbai's most prestigious clubs after surprise inspections uncovered widespread hygiene and food safety violations.The action follows inspections conducted between July 24 and July 27 under the supervision of FDA Commissioner Tukaram Mundhe, who has intensified enforcement against food safety violations across Maharashtra. Officials said the violations were serious and systemic, posing a potential public health risk.Five clubs whose FSSAI food licences have been suspended:<ol><li>Cricket Club of India (CCI)</li><li>MIG Cricket Club</li><li>Willingdon Sports Club</li><li>RK Juhu Gymkhana</li><li>Aparna Juhu Gymkhana</li></ol>The clubs have been directed to halt food operations until all deficiencies are rectified and compliance with the Food Safety and Standards Act, 2006, is verified by the FDA.<h2>Cockroaches, rotten food and unhygienic kitchens</h2>According to the FDA, inspectors found multiple violations across kitchens, storage facilities and food preparation areas.At the Cricket Club of India (CCI), officials found live cockroach and fly infestations in food preparation and waste disposal areas, rotten vegetables, overripe mushrooms and expired food items. Water was reportedly dripping onto stored food inside cold storage, while clogged drains, grease accumulation and stagnant water were found near the kitchen. Inspectors also flagged the absence of segregation between vegetarian and non-vegetarian food preparation, poor food labelling practices, failure to follow First-In-First-Out (FIFO) and First-Expired-First-Out (FEFO) storage protocols, and unhygienic utensils and cutting boards placed directly on the floor.At MIG Cricket Club, the FDA found an unauthorised caterer operating without a valid FSSAI licence. Officials also reported cockroach infestation, cobwebs inside the kitchen, improper storage of raw and cooked food, absence of periodic food and water testing, lack of mandatory health records for food handlers and failure to notify authorities about management-related changes.At Willingdon Sports Club, RK Juhu Gymkhana and Aparna Juhu Gymkhana, inspectors found poor pest control measures, rusted and corroded food-processing equipment, unhygienic kitchens, improper storage of food ingredients and several lapses in food safety documentation and hygiene compliance.<h2>Mumbai's oldest and most prestigious clubs</h2>The action is significant because it targets institutions that have long been considered among Mumbai's most exclusive sporting and social clubs.Founded in 1933, the Cricket Club of India is one of India's most iconic cricket institutions and the custodian of the historic Brabourne Stadium, which has hosted numerous international cricket matches.Willingdon Sports Club, established in 1918, is among Mumbai's oldest elite recreational clubs, known for tennis, squash, swimming and other sporting facilities.Founded in 1969, MIG Cricket Club has played a major role in Mumbai's cricketing ecosystem and has produced several first-class and international cricketers.RK Juhu Gymkhana and Aparna Juhu Gymkhana are well-known private clubs in Mumbai's western suburbs, catering to thousands of members through sports, dining and social events.<h2>Wider crackdown continues</h2>The inspection drive covered seven food establishments across Mumbai. Besides suspending the licences of the five clubs, the FDA also issued a Stop Business Notice to Goregaon Sports Club for allegedly operating its food business without a valid FSSAI licence, while another establishment was served with an improvement notice.The crackdown follows a series of high-profile enforcement actions by the Maharashtra FDA against restaurants, clubs and food businesses across the state. Commissioner Tukaram Mundhe has repeatedly stated that no establishment—regardless of its reputation or clientele—will be exempt from food safety regulations.The suspended clubs will be allowed to resume food operations only after rectifying all deficiencies and obtaining clearance from the FDA.&nbsp;

The Maharashtra Food and Drug Administration has suspended the FSSAI food business licences of five prominent Mumbai clubs, including the Cricket Club of India and Willingdon Sports Club, after surprise inspections uncovered serious hygiene violations.

Mumbai: In one of Maharashtra's biggest food safety crackdowns targeting high-profile establishments, the state's Food and Drug Administration (FDA) has suspended the FSSAI food business licences of five of Mumbai's most prestigious clubs after surprise inspections uncovered widespread hygiene and food safety violations. The action follows inspections conducted between July 24 and July 27 under the supervision of FDA Commissioner Tukaram Mundhe, who has intensified enforcement against food safety violations across Maharashtra. Officials said the violations were serious and systemic, posing a potential public health risk. Five clubs whose FSSAI food licences have been suspended: Cricket Club of India (CCI) MIG Cricket Club Willingdon Sports Club RK Juhu Gymkhana Aparna Juhu Gymkhana The clubs have been directed to halt food operations until all deficiencies are rectified and compliance with the Food Safety and Standards Act, 2006, is verified by the FDA. Cockroaches, rotten food and unhygienic kitchens According to the FDA, inspectors found multiple violations across kitchens, storage facilities and food preparation areas. At the Cricket Club of India (CCI), officials found live cockroach and fly infestations in food preparation and waste disposal areas, rotten vegetables, overripe mushrooms and expired food items. Water was reportedly dripping onto stored food inside cold storage, while clogged drains, grease accumulation and stagnant water were found near the kitchen. Inspectors also flagged the absence of segregation between vegetarian and non-vegetarian food preparation, poor food labelling practices, failure to follow First-In-First-Out (FIFO) and First-Expired-First-Out (FEFO) storage protocols, and unhygienic utensils and cutting boards placed directly on the floor. At MIG Cricket Club, the FDA found an unauthorised caterer operating without a valid FSSAI licence. Officials also reported cockroach infestation, cobwebs inside the kitchen, improper storage of raw and cooked food, absence of periodic food and water testing, lack of mandatory health records for food handlers and failure to notify authorities about management-related changes. At Willingdon Sports Club, RK Juhu Gymkhana and Aparna Juhu Gymkhana, inspectors found poor pest control measures, rusted and corroded food-processing equipment, unhygienic kitchens, improper storage of food ingredients and several lapses in food safety documentation and hygiene compliance. Mumbai's oldest and most prestigious clubs The action is significant because it targets institutions that have long been considered among Mumbai's most exclusive sporting and social clubs. Founded in 1933, the Cricket Club of India is one of India's most iconic cricket institutions and the custodian of the historic Brabourne Stadium, which has hosted numerous international cricket matches. Willingdon Sports Club, established in 1918, is among Mumbai's oldest elite recreational clubs, known for tennis, squash, swimming and other sporting facilities. Founded in 1969, MIG Cricket Club has played a major role in Mumbai's cricketing ecosystem and has produced several first-class and international cricketers. RK Juhu Gymkhana and Aparna Juhu Gymkhana are well-known private clubs in Mumbai's western suburbs, catering to thousands of members through sports, dining and social events. Wider crackdown continues The inspection drive covered seven food establishments across Mumbai. Besides suspending the licences of the five clubs, the FDA also issued a Stop Business Notice to Goregaon Sports Club for allegedly operating its food business without a valid FSSAI licence, while another establishment was served with an improvement notice. The crackdown follows a series of high-profile enforcement actions by the Maharashtra FDA against restaurants, clubs and food businesses across the state. Commissioner Tukaram Mundhe has repeatedly stated that no establishment—regardless of its reputation or clientele—will be exempt from food safety regulations. The suspended clubs will be allowed to resume food operations only after rectifying all deficiencies and obtaining clearance from the FDA.

The Maharashtra Food and Drug Administration has suspended the FSSAI food business licences of five prominent Mumbai clubs, including the Cricket Club of India and Willingdon Sports Club, after surprise inspections uncovered serious hygiene violations.

Mumbai's elite clubs under scanner: FDA suspends food licences of five iconic clubs over serious hygiene violations

The U.S. FDA approved a pill version of the weight-loss injection 'Wegovy', which is likely to be launched in January 2026. During its clinical trials, close to 1300 participants experienced an average weight loss of 16.6% after 64 weeks. Meanwhile, Orforglipron- an oral pill manufactured by U.S. drugmaker Eli Lilly is awaiting regulatory clearance.


US drug regulator approves first-of-its-kind anti-obesity pill 'Wegovy'

The US Food and Drug Administration (FDA) on Monday (Dec 22) approved the first daily pill version of Novo Nordisk’s popular weight loss drug Wegovy, revolutionising the way to treat obesity. The move has also given the drugmaker an edge over its rival Eli Lilly, whose oral drug orforglipron, is still under review. The GLP-1 drug uses the same active ingredient, semaglutide, that powers Wegovy and its sister drug Ozempic, which is used for diabetes.Both Wegovy and Ozempic are widely used as injections. The drug mimics a natural hormone that controls appetite and feelings of fullness. While the FDA had already approved a pill to be used for treating diabetes, the approval of the weight loss drug will allow doctors to prescribe the pill to patients with obesity or those who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said.“With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement.According to the US Centers for Disease Control and Prevention (CDC), about 40 per cent of American adults have a prevalence of obesity. The new development was lauded by the US Obesity Care Advocacy Network (OCAN), a nonprofit advocacy group for adults with obesity.“This development represents an important opportunity for people living with obesity, offering an alternative for those hesitant to begin injectable therapy and providing a potentially lower-cost option,” the group said in a statement to AFP.According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs, CBS reported, citing experts.During a clinical trial, the oral Wegovy resulted in a weight loss of 13.6 per cent of the total body weight of participants in about 15 months, which is nearly the same as injectable Wegovy, with an average weight loss of about 15 per cent.

According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs

The US Food and Drug Administration (FDA) on Monday (Dec 22) approved the first daily pill version of Novo Nordisk’s popular weight loss drug Wegovy, revolutionising the way to treat obesity. The move has also given the drugmaker an edge over its rival Eli Lilly, whose oral drug orforglipron, is still under review. The GLP-1 drug uses the same active ingredient, semaglutide, that powers Wegovy and its sister drug Ozempic, which is used for diabetes. Both Wegovy and Ozempic are widely used as injections. The drug mimics a natural hormone that controls appetite and feelings of fullness. While the FDA had already approved a pill to be used for treating diabetes, the approval of the weight loss drug will allow doctors to prescribe the pill to patients with obesity or those who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said. “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement. According to the US Centers for Disease Control and Prevention (CDC), about 40 per cent of American adults have a prevalence of obesity. The new development was lauded by the US Obesity Care Advocacy Network (OCAN), a nonprofit advocacy group for adults with obesity. “This development represents an important opportunity for people living with obesity, offering an alternative for those hesitant to begin injectable therapy and providing a potentially lower-cost option,” the group said in a statement to AFP. According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs, CBS reported, citing experts. During a clinical trial, the oral Wegovy resulted in a weight loss of 13.6 per cent of the total body weight of participants in about 15 months, which is nearly the same as injectable Wegovy, with an average weight loss of about 15 per cent.

According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs.

No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill – All you need to know

The U.S. (FDA) has launched a comprehensive probe into deaths potentially linked to COVID-19 vaccines. According to an internal memo by its vaccine regulator, the shot may have contributed to the deaths of at least 10 children, prompting plans for stricter vaccine-approval standards and stronger oversight. This video breaks down what is currently known — the scope of the investigation, the concerns raised, reactions from vaccine makers, and what the developments could mean for future immunisation policies globally.

FDA Probes Deaths Likely Related To COVID Jab: Plans To Tighten Vaccine Oversight

A deadly E. coli outbreak hit 15 US states at the end of last year, leading to one death and over 80 falling sick. However, the Food and Drug Administration (FDA) kept it a secret and did not disclose it to the public, NBC News reported.
In November last year, the outbreak spread across the states, leaving dozens of people sick. It further led to the death of a nine-year-old boy who died of kidney failure.&nbsp;
Also read: <a href="https://www.wionews.com/world/health-crisis-in-uk-over-100-ill-following-e-coli-outbreak-says-ukhsa-729470">Health crisis in UK: Over 100 ill following E coli outbreak, says UKHSA</a>
<h2>What caused the outbreak?</h2>
The deadly E. coli outbreak was linked to romaine lettuce. Also, a 57-year-old woman in Missouri became seriously ill after eating lettuce at a funeral lunch.&nbsp;
According to NBC, the agency did not name the produce company involved in the outbreak and kept it secret, hiding the information from the public.&nbsp;
The investigation was then quietly closed in February 2025, according to an internal report.&nbsp;
Also read: <a href="https://www.wionews.com/world/no-more-food-safety-inspections-in-us-fdas-new-plan-unveiled-amid-massive-staff-cuts-8976954">No more food safety inspections in US? FDA's new plan unveiled amid massive staff cuts</a>
However, while defending itself, the <a href="https://www.wionews.com/world/fda-scientists-told-not-to-use-words-women-disabled-elderly-white-house-calls-it-an-error-8740866">FDA </a>said that it did not release information about the outbreak because by the time it determined the likely source, the contaminated lettuce was no longer available in stores.
"There were no public communications related to this outbreak," the FDA stated in the internal report.
A spokesperson said that the agency only names firms when there is clear evidence and a public health action can be taken.&nbsp;
<h2>People call it 'disturbing'&nbsp;</h2>
After the information went public, some experts reacted to FDA's hidden secret, disagreeing with their decision not to inform the public about the outbreak.&nbsp;
Frank Yiannas, who served as deputy commissioner of food policy at the FDA from 2018 to 2023, called the lack of transparency "disturbing."
"It is disturbing that the FDA hasn't said anything more public or identified the name of a grower or processor," said Yiannas.
"People have a right to know who's selling contaminated products," Sandra Eskin, a former Department of Agriculture official said.&nbsp;
WATCH | <a href="https://www.wionews.com/videos/us-fda-approves-first-new-uti-drug-in-decades-8898199">US FDA approves first new UTI drug in decades</a>

The deadly E. coli outbreak was linked to romaine lettuce. Also, a 57-year-old woman in Missouri became seriously ill after eating lettuce at a funeral lunch. WORLD

A deadly E. coli outbreak hit 15 US states at the end of last year, leading to one death and over 80 falling sick. However, the Food and Drug Administration (FDA) kept it a secret and did not disclose it to the public, NBC News reported. In November last year, the outbreak spread across the states, leaving dozens of people sick. It further led to the death of a nine-year-old boy who died of kidney failure. Also read: Health crisis in UK: Over 100 ill following E coli outbreak, says UKHSA What caused the outbreak? The deadly E. coli outbreak was linked to romaine lettuce. Also, a 57-year-old woman in Missouri became seriously ill after eating lettuce at a funeral lunch. According to NBC, the agency did not name the produce company involved in the outbreak and kept it secret, hiding the information from the public. The investigation was then quietly closed in February 2025, according to an internal report. Also read: No more food safety inspections in US? FDA's new plan unveiled amid massive staff cuts However, while defending itself, the FDA said that it did not release information about the outbreak because by the time it determined the likely source, the contaminated lettuce was no longer available in stores. "There were no public communications related to this outbreak," the FDA stated in the internal report. A spokesperson said that the agency only names firms when there is clear evidence and a public health action can be taken. People call it 'disturbing' After the information went public, some experts reacted to FDA's hidden secret, disagreeing with their decision not to inform the public about the outbreak. Frank Yiannas, who served as deputy commissioner of food policy at the FDA from 2018 to 2023, called the lack of transparency "disturbing." "It is disturbing that the FDA hasn't said anything more public or identified the name of a grower or processor," said Yiannas. "People have a right to know who's selling contaminated products," Sandra Eskin, a former Department of Agriculture official said. WATCH | US FDA approves first new UTI drug in decades

US government's BIG secret out: FDA kept deadly E. coli outbreak in 15 states hidden. Here's what caused it

The US Food and Drug Administration <a href="https://www.wionews.com/health-and-wellness/fda-issues-highest-risk-warning-for-recalled-chocolates-and-other-related-items-8682952">(FDA)</a>&nbsp;has been making a plan to end most of its routine food safety inspections work amid major staff cuts at the Department of Health and Human Services (HHS), multiple federal health officials told CBS News.&nbsp;
The proficiency testing program of the FDA&rsquo;s Food Emergency Response Network was made to ensure consistency and accuracy across the agency's network of about 170 labs that test food for pathogens.&nbsp;
This comes after 20,000 HHS employees got fired or some departed, leading to disruption in the agency's work on areas including bird flu and drug reviews.&nbsp;
WATCH |<a href="https://www.wionews.com/videos/us-fda-approves-first-new-uti-drug-in-decades-8898199">US FDA approves first new UTI drug in decades</a>
Meanwhile, US President Donald Trump has been hoping to slash as much as $40 billion from HHS.
&ldquo;Unfortunately, significant reductions in force, including a key quality assurance officer, an analytical chemist, and two microbiologists at FDA&rsquo;s Human Food Program Moffett Center have an immediate and significant impact on the Food Emergency Response Network (FERN) Proficiency Testing (PT) Program,&rdquo; said the email sent on Tuesday from FERN&rsquo;s National Program Office and seen by Reuters.
The program will be suspended at least from September 30. It further means that the agency will be unable to do planned quality-check on food for &nbsp;the parasite cyclospora in spinach or the pesticide glyphosate in barley, among other tests, the email read.&nbsp;
Also read: <a href="https://www.wionews.com/world/fda-scientists-told-not-to-use-words-women-disabled-elderly-white-house-calls-it-an-error-8740866">FDA scientists told not to use words &lsquo;women&rsquo;, &lsquo;disabled&rsquo;, &lsquo;elderly&rsquo;; White House calls it &lsquo;error&rsquo;</a>
&ldquo;These PTs and Exercises are critical to demonstrating the competency and readiness of our laboratory network to detect and respond to food safety and food defense events,&rdquo; it added.
According to CBS report, the FDA plans may need congressional action to fully fund, adding that some higher-risk routine food inspections would probably remain at the FDA.
Notably, in April, the FDA suspended an effort to improve its testing for bird flu in milk, cheese and pet food due to staff shortage.&nbsp;
Also read: <a href="https://www.wionews.com/health-and-wellness/us-fda-approved-nasal-spray-available-for-treatment-resistant-depression-in-america-8652812">A first of its kind: US FDA-approved nasal spray available for treatment-resistant depression in America</a>

This comes after 20,000 HHS employees got fired or some departed, leading to disruption in the agency's work on areas including bird flu and drug reviews. WORLD

The US Food and Drug Administration (FDA) has been making a plan to end most of its routine food safety inspections work amid major staff cuts at the Department of Health and Human Services (HHS), multiple federal health officials told CBS News. The proficiency testing program of the FDA’s Food Emergency Response Network was made to ensure consistency and accuracy across the agency's network of about 170 labs that test food for pathogens. This comes after 20,000 HHS employees got fired or some departed, leading to disruption in the agency's work on areas including bird flu and drug reviews. WATCH |US FDA approves first new UTI drug in decades Meanwhile, US President Donald Trump has been hoping to slash as much as $40 billion from HHS. “Unfortunately, significant reductions in force, including a key quality assurance officer, an analytical chemist, and two microbiologists at FDA’s Human Food Program Moffett Center have an immediate and significant impact on the Food Emergency Response Network (FERN) Proficiency Testing (PT) Program,” said the email sent on Tuesday from FERN’s National Program Office and seen by Reuters. The program will be suspended at least from September 30. It further means that the agency will be unable to do planned quality-check on food for the parasite cyclospora in spinach or the pesticide glyphosate in barley, among other tests, the email read. Also read: FDA scientists told not to use words ‘women’, ‘disabled’, ‘elderly’; White House calls it ‘error’ “These PTs and Exercises are critical to demonstrating the competency and readiness of our laboratory network to detect and respond to food safety and food defense events,” it added. According to CBS report, the FDA plans may need congressional action to fully fund, adding that some higher-risk routine food inspections would probably remain at the FDA. Notably, in April, the FDA suspended an effort to improve its testing for bird flu in milk, cheese and pet food due to staff shortage. Also read: A first of its kind: US FDA-approved nasal spray available for treatment-resistant depression in America

No more food safety inspections in US? FDA's new plan unveiled amid massive staff cuts

The US Food and Drug Administration has approved a groundbreaking new treatment for urinary tract infections or UTI. This treatment could perhaps be a game-changer in the fight against antibiotic resistance. This is the first such drug to be approved in nearly three decades.

US FDA approves first new UTI drug in decades

Some of the Food and Drug Administration (FDA) scientists have been told to stop using the words "woman", "disabled", and "elderly" in external communications, Reuters reported, citing two sources familiar with the matter.&nbsp;
The FDA scientists said that a list with the file name "prohibited words" has been circulating since at least last week in official chats.&nbsp;
As the issue came under the spotlight, the White House spokesman said that a part of the list of banned terms had misinterpreted President Donald Trump's executive order.&nbsp;
Also read: <a href="https://www.wionews.com/world/deloitte-orders-us-staff-to-remove-gender-pronouns-from-email-amid-trumps-crackdown-on-transgenders-8712132">Deloitte orders US staff to remove gender pronouns from email amid Trump's crackdown on transgenders</a>
The list is creating further confusion at an agency struggling with the Trump administration's sweeping firings.&nbsp;
Two FDA scientists, who requested anonymity, said that neither they nor their managers knew who issued the directive or why many of the more than two dozen words were included.&nbsp;
"I don't understand why we can't use a word like 'woman'," one FDA source who received the list told Reuters. "The words on the list would make it almost impossible to do our jobs."
The list reviewed by Reuters includes words like underrepresented, underserved, understudied, sex, identity, diverse, women, woman, promote, definition, continuum, ideology, self-assessed, special populations, elderly, and disabled.
Also read: <a href="https://www.wionews.com/world/transgenders-people-with-history-of-gender-dysphoria-can-no-longer-join-us-military-defense-secretary-hegseth-memo-enforces-trumps-order-8709166">Transgenders, people with 'history of gender dysphoria' can no longer join US military: Hegseth memo</a>
Meanwhile, in recent weeks, another federal health agency was told to remove words such as gender, transgender, LGBT, and nonbinary from its communications to ensure that they comply with executive orders.&nbsp;
To follow the order, the Centers for Disease Control and Prevention removed publicly available health information, including HIV datasets, and withdrew research papers that were being considered for publication in scientific journals for review by Trump appointees.&nbsp;
Also read: <a href="https://www.wionews.com/world/american-transgenders-woe-as-passport-process-gets-complicated-for-them-amid-trumps-new-policy-8703305">Transgender Americans face complicated passport process amid Trump's new policy</a>
<h2>White House calls it an &lsquo;error&rsquo;</h2>
The White House spokesman told Reuters that most of the words on the FDA list did not need to be removed from communications, adding that an error may have resulted from the FDA officials misinterpreting Trump's executive order against "gender ideology."
Further clarifying, the spokesman said that the FDA does need to prohibit the use of the words gender, inclusion, identity, diversity, inter, intersex, equity, equitable, transgender, and trans to comply with the order.
Also read: <a href="https://www.wionews.com/world/trump-to-sign-executive-order-banning-transgender-from-female-sports-8694059">Trump to sign executive order banning transgender athletes from female sports</a>
<h2>Public health experts react</h2>
The experts stressed that such a move can threaten their ability to address all kinds of medical needs as they affect different groups, including those with HIV and sexually transmitted diseases.&nbsp;
Moreover, the two FDA sources said that their colleagues told them the list had originated within the Center for Devices and Radiological Health, which has more than 2,000 workers and is tasked with ensuring the safety and efficacy of medical devices.
(With inputs from agencies)

World: As the issue came under the spotlight, the White House spokesman said that a part of the list of banned terms had misinterpreted President Donald Trump’s executive order.

Some of the Food and Drug Administration (FDA) scientists have been told to stop using the words "woman", "disabled", and "elderly" in external communications, Reuters reported, citing two sources familiar with the matter. The FDA scientists said that a list with the file name "prohibited words" has been circulating since at least last week in official chats. As the issue came under the spotlight, the White House spokesman said that a part of the list of banned terms had misinterpreted President Donald Trump's executive order. Also read: Deloitte orders US staff to remove gender pronouns from email amid Trump's crackdown on transgenders The list is creating further confusion at an agency struggling with the Trump administration's sweeping firings. Two FDA scientists, who requested anonymity, said that neither they nor their managers knew who issued the directive or why many of the more than two dozen words were included. "I don't understand why we can't use a word like 'woman'," one FDA source who received the list told Reuters. "The words on the list would make it almost impossible to do our jobs." The list reviewed by Reuters includes words like underrepresented, underserved, understudied, sex, identity, diverse, women, woman, promote, definition, continuum, ideology, self-assessed, special populations, elderly, and disabled. Also read: Transgenders, people with 'history of gender dysphoria' can no longer join US military: Hegseth memo Meanwhile, in recent weeks, another federal health agency was told to remove words such as gender, transgender, LGBT, and nonbinary from its communications to ensure that they comply with executive orders. To follow the order, the Centers for Disease Control and Prevention removed publicly available health information, including HIV datasets, and withdrew research papers that were being considered for publication in scientific journals for review by Trump appointees. Also read: Transgender Americans face complicated passport process amid Trump's new policy White House calls it an ‘error’ The White House spokesman told Reuters that most of the words on the FDA list did not need to be removed from communications, adding that an error may have resulted from the FDA officials misinterpreting Trump's executive order against "gender ideology." Further clarifying, the spokesman said that the FDA does need to prohibit the use of the words gender, inclusion, identity, diversity, inter, intersex, equity, equitable, transgender, and trans to comply with the order. Also read: Trump to sign executive order banning transgender athletes from female sports Public health experts react The experts stressed that such a move can threaten their ability to address all kinds of medical needs as they affect different groups, including those with HIV and sexually transmitted diseases. Moreover, the two FDA sources said that their colleagues told them the list had originated within the Center for Devices and Radiological Health, which has more than 2,000 workers and is tasked with ensuring the safety and efficacy of medical devices. (With inputs from agencies)

FDA scientists told not to use words ‘women’, ‘disabled’, ‘elderly’; White House calls it ‘error’

A California-based snack company, Cal Yee Farm LLC, has issued a recall for several chocolate and yogurt-covered products after the U.S. Food and Drug Administration (FDA) classified them under Class I, the highest risk level. The recall follows the discovery of undeclared allergens, including milk, soy, wheat, sesame, synthetic dye, and almonds, in some of the company's products. These allergens could potentially trigger severe allergic reactions in sensitive individuals. Watch in for more details!

Cal Yee products recalled after FDA inspection

The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been approved to treat this condition.

<h2>The link between obesity and sleep apnea</h2>

Obstructive sleep apnea is a serious condition that disrupts breathing and sleep and is commonly associated with obesity. Many individuals experience improvements in their sleep apnea symptoms as they lose weight, suggesting that weight loss may play a key role in managing the disorder. The expanded approval of Zepbound, which aids in weight loss, is expected to help improve sleep apnea in affected individuals.

Currently, obstructive sleep apnea is only treated with a positive airway pressure (PAP) device, as there is no approved medication for the condition. Zepbound’s approval for use in sleep apnea means that insurance providers, including Medicare, are likely to cover its cost for individuals with both obesity and sleep apnea. This is a significant change, as many insurance plans do not reimburse treatments for obesity alone.

Also read |&nbsp;<a href="https://www.wionews.com/world/mystery-illness-dinga-dinga-leaves-300-in-uganda-shaking-uncontrollably-785363">Mystery illness 'Dinga Dinga' leaves 300 in Uganda shaking uncontrollably</a>

<h2>Targeting obesity-related sleep apnea</h2>

The new approval applies to adults with moderate to severe obstructive sleep apnea who also have obesity, a group estimated to number between 15 to 20 million people in the US.

Common signs of sleep apnea include loud snoring, breathing pauses during sleep, daytime drowsiness, forgetfulness and morning headaches. These symptoms can result in serious health problems if left untreated.

Also read |&nbsp;<a href="https://www.wionews.com/science/aging-a-thing-of-the-past-new-study-finds-70-is-the-new-60-785451">Ageing a thing of the past? New study finds 70 is the new 60 because...</a>

<h2>How Zepbound works in sleep apnea treatment</h2>

While the exact mechanism by which Zepbound improves sleep apnea symptoms remains unclear, it is believed that the weight loss associated with the drug may be the key factor.

Zepbound contains tirzepatide, which may also have other effects on the body. In clinical trials, participants using Zepbound lost an average of 20 per cent of their body weight, which likely contributed to improvements in their sleep apnea symptoms.

(With inputs from agencies)

The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been approved to treat this condition.

The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been approved to treat this condition. The link between obesity and sleep apnea Obstructive sleep apnea is a serious condition that disrupts breathing and sleep and is commonly associated with obesity. Many individuals experience improvements in their sleep apnea symptoms as they lose weight, suggesting that weight loss may play a key role in managing the disorder. The expanded approval of Zepbound, which aids in weight loss, is expected to help improve sleep apnea in affected individuals. Currently, obstructive sleep apnea is only treated with a positive airway pressure (PAP) device, as there is no approved medication for the condition. Zepbound’s approval for use in sleep apnea means that insurance providers, including Medicare, are likely to cover its cost for individuals with both obesity and sleep apnea. This is a significant change, as many insurance plans do not reimburse treatments for obesity alone. Also read | Mystery illness 'Dinga Dinga' leaves 300 in Uganda shaking uncontrollably Targeting obesity-related sleep apnea The new approval applies to adults with moderate to severe obstructive sleep apnea who also have obesity, a group estimated to number between 15 to 20 million people in the US. Common signs of sleep apnea include loud snoring, breathing pauses during sleep, daytime drowsiness, forgetfulness and morning headaches. These symptoms can result in serious health problems if left untreated. Also read | Ageing a thing of the past? New study finds 70 is the new 60 because... How Zepbound works in sleep apnea treatment While the exact mechanism by which Zepbound improves sleep apnea symptoms remains unclear, it is believed that the weight loss associated with the drug may be the key factor. Zepbound contains tirzepatide, which may also have other effects on the body. In clinical trials, participants using Zepbound lost an average of 20 per cent of their body weight, which likely contributed to improvements in their sleep apnea symptoms. (With inputs from agencies)

FDA expands weight loss drug Zepbound approval to treat sleep apnea

Washington DC, United States
The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been approved to treat this condition.
<h2>The link between obesity and sleep apnea</h2>
Obstructive sleep apnea is a serious condition that disrupts breathing and sleep and is commonly associated with obesity. Many individuals experience improvements in their sleep apnea symptoms as they lose weight, suggesting that weight loss may play a key role in managing the disorder. The expanded approval of Zepbound, which aids in weight loss, is expected to help improve sleep apnea in affected individuals.
Currently, obstructive sleep apnea is only treated with a positive airway pressure (PAP) device, as there is no approved medication for the condition. Zepbound’s approval for use in sleep apnea means that insurance providers, including Medicare, are likely to cover its cost for individuals with both obesity and sleep apnea. This is a significant change, as many insurance plans do not reimburse treatments for obesity alone.
Also read | <a href="https://www.wionews.com/world/mystery-illness-dinga-dinga-leaves-300-in-uganda-shaking-uncontrollably-785363">Mystery illness 'Dinga Dinga' leaves 300 in Uganda shaking uncontrollably</a>
<h2>Targeting obesity-related sleep apnea</h2>
The new approval applies to adults with moderate to severe obstructive sleep apnea who also have obesity, a group estimated to number between 15 to 20 million people in the US.
Common signs of sleep apnea include loud snoring, breathing pauses during sleep, daytime drowsiness, forgetfulness and morning headaches. These symptoms can result in serious health problems if left untreated.
Also read | <a href="https://www.wionews.com/science/aging-a-thing-of-the-past-new-study-finds-70-is-the-new-60-785451">Ageing a thing of the past? New study finds 70 is the new 60 because...</a>
<h2>How Zepbound works in sleep apnea treatment</h2>
While the exact mechanism by which Zepbound improves sleep apnea symptoms remains unclear, it is believed that the weight loss associated with the drug may be the key factor.
Zepbound contains tirzepatide, which may also have other effects on the body. In clinical trials, participants using Zepbound lost an average of 20 per cent of their body weight, which likely contributed to improvements in their sleep apnea symptoms.
(With inputs from agencies)

Obstructive sleep apnea is a serious condition that disrupts breathing and sleep and is commonly associated with obesity. 



Washington DC, United States The FDA has approved Eli Lilly’s obesity treatment, Zepbound, for the management of moderate to severe obstructive sleep apnea in people with obesity. This marks the first time a medication has been approved to treat this condition. The link between obesity and sleep apnea Obstructive sleep apnea is a serious condition that disrupts breathing and sleep and is commonly associated with obesity. Many individuals experience improvements in their sleep apnea symptoms as they lose weight, suggesting that weight loss may play a key role in managing the disorder. The expanded approval of Zepbound, which aids in weight loss, is expected to help improve sleep apnea in affected individuals. Currently, obstructive sleep apnea is only treated with a positive airway pressure (PAP) device, as there is no approved medication for the condition. Zepbound’s approval for use in sleep apnea means that insurance providers, including Medicare, are likely to cover its cost for individuals with both obesity and sleep apnea. This is a significant change, as many insurance plans do not reimburse treatments for obesity alone. Also read | Mystery illness 'Dinga Dinga' leaves 300 in Uganda shaking uncontrollably Targeting obesity-related sleep apnea The new approval applies to adults with moderate to severe obstructive sleep apnea who also have obesity, a group estimated to number between 15 to 20 million people in the US. Common signs of sleep apnea include loud snoring, breathing pauses during sleep, daytime drowsiness, forgetfulness and morning headaches. These symptoms can result in serious health problems if left untreated. Also read | Ageing a thing of the past? New study finds 70 is the new 60 because... How Zepbound works in sleep apnea treatment While the exact mechanism by which Zepbound improves sleep apnea symptoms remains unclear, it is believed that the weight loss associated with the drug may be the key factor. Zepbound contains tirzepatide, which may also have other effects on the body. In clinical trials, participants using Zepbound lost an average of 20 per cent of their body weight, which likely contributed to improvements in their sleep apnea symptoms. (With inputs from agencies)

The brain-chip startup of Elon Musk's Neuralink&nbsp;has now announced Blindsight - an experimental vision-restoring implant - which will attempt to give vision to the blind.&nbsp;

The company announced that the US Food and Drug Administration (FDA) on Tuesday (September 17) called Blindsight a “breakthrough device”.&nbsp;

Also Read:&nbsp;<a href="https://www.wionews.com/trending/elon-musks-neuralink-successfully-implants-brain-chip-in-second-patient-747164">Elon Musk's Neuralink successfully implants brain chip in second patient</a>

With this announcement, the device entered the group of cutting-edge medical technologies which have been designed for treating serious health conditions.

<h2>What is Neuralink’s Blindsight?</h2>

Blindsight is an attempt made by Neuralink to restore the lost vision of people, even in those cases where they have lost both eyes as well as their optic nerve.

Speaking about the device on X, Musk said that this breakthrough will “enable even those who have lost both eyes and their optic nerve to see.”

However, no announcement has been made by Neuralink on the timeline for human trials.

The Blindsight device will work by implanting a microelectrode array directly inside the brain's visual cortex.&nbsp;

The neurons are activated by the array on the basis of input from an external camera which creates a visual image.&nbsp;

Watch:&nbsp;Mind-controlled Chess move makes history at Paris Championship

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/mind-controlled-chess-move-makes-history-at-paris-championship-757932/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

In theory, this technology can also provide a type of artificial vision for people who have not seen at all in their entire lives and are born blind.

This is not the first time scientists have tried such a technology. In the past, similar devices have been used to support vision in partially sighted people.

Neuralink, however, stands different from other brain-computer interface projects in trying to add more electrodes to the implant which has the possibility of increasing the vividness of the vision of the user.&nbsp;

But how much vision would Blindsight actually restore is still a question.&nbsp;

(With inputs from agencies)

The brain-chip startup of Elon Musk's Neuralink has now announced Blindsight - an experimental vision-restoring implant - which will attempt to give vision to the blind.

The brain-chip startup of Elon Musk's Neuralink has now announced Blindsight - an experimental vision-restoring implant - which will attempt to give vision to the blind. The company announced that the US Food and Drug Administration (FDA) on Tuesday (September 17) called Blindsight a “breakthrough device”. Also Read: Elon Musk's Neuralink successfully implants brain chip in second patient With this announcement, the device entered the group of cutting-edge medical technologies which have been designed for treating serious health conditions. What is Neuralink’s Blindsight? Blindsight is an attempt made by Neuralink to restore the lost vision of people, even in those cases where they have lost both eyes as well as their optic nerve. Speaking about the device on X, Musk said that this breakthrough will “enable even those who have lost both eyes and their optic nerve to see.” However, no announcement has been made by Neuralink on the timeline for human trials. The Blindsight device will work by implanting a microelectrode array directly inside the brain's visual cortex. The neurons are activated by the array on the basis of input from an external camera which creates a visual image. Watch: Mind-controlled Chess move makes history at Paris Championship In theory, this technology can also provide a type of artificial vision for people who have not seen at all in their entire lives and are born blind. This is not the first time scientists have tried such a technology. In the past, similar devices have been used to support vision in partially sighted people. Neuralink, however, stands different from other brain-computer interface projects in trying to add more electrodes to the implant which has the possibility of increasing the vividness of the vision of the user. But how much vision would Blindsight actually restore is still a question. (With inputs from agencies)

Musk’s Neuralink announces Blindsight to provide vision to blind, gets FDA's approval

The Food and Drug Administration (FDA) of the United States has found bacterial contamination in nearly half of permanent makeup (PMU) ink samples and about a quarter of tattoo ink products. The samples also included products from&nbsp;popular brands that claim to be "sterile."

The scientists tested 75 tattoo and PMU inks for the presence of aerobic and anaerobic bacteria, the findings of which were published in the Applied and Environmental Microbiology journal on Tuesday (Jul 2).

With the growing trend of using tattoos and PMU inks, the FDA has warned people of contamination in these products which have previously resulted in outbreaks of infections. The FDA also issued guidelines for tattoo ink manufacturers and distributors last year, urging them to take precautions and prevent contamination by microorganisms.

Also Read |&nbsp;<a href="https://www.wionews.com/science/venezuela-archaeologists-discover-ancient-rock-art-sites-from-a-previously-unknown-culture-737352">Venezuela archaeologists discover ancient rock art sites from a 'previously unknown' culture</a>

Researchers examined 49 tattoo ink samples, out of which nine had bacterial growth. While testing for PMU inks, 17 out of 35 were found to be contaminated.

It was also discovered that 35 per cent&nbsp;of the sealed and unopened inks which were tested had both aerobic and anaerobic bacteria contamination.

Aerobic bacteria are bacteria which can survive and grow in the presence of oxygen, while anaerobic bacteria can survive even without the presence of oxygen. They can live in the dermal skin layer and injured human tissue.

It is not immediately known&nbsp;which brands were included in the study and whether the FDA took any measures against the brands of which products were found to be contaminated.

Also Read |&nbsp;<a href="https://www.wionews.com/science/turns-out-ancient-egyptian-writers-also-suffered-from-consequences-of-hunching-over-your-devices-737355">Ancient Egyptian writers also hunched over devices and suffered the consequences</a>

Researchers claim that the sterilisation process undertaken by brands is either ineffective or their claims are false regarding them being "sterile".

Previously, it was believed that tattoo-related infections and complications are caused by allergic and inflammatory reactions due to improper hygiene. However, recent studies have pointed out that contamination of the ink may also be the reason.

(With inputs from agencies)

The Food and Drug Administration (FDA) of the United States has found bacterial contamination in nearly half of permanent makeup (PMU) ink samples and about a quarter of tattoo ink products.

The Food and Drug Administration (FDA) of the United States has found bacterial contamination in nearly half of permanent makeup (PMU) ink samples and about a quarter of tattoo ink products. The samples also included products from popular brands that claim to be "sterile." The scientists tested 75 tattoo and PMU inks for the presence of aerobic and anaerobic bacteria, the findings of which were published in the Applied and Environmental Microbiology journal on Tuesday (Jul 2). With the growing trend of using tattoos and PMU inks, the FDA has warned people of contamination in these products which have previously resulted in outbreaks of infections. The FDA also issued guidelines for tattoo ink manufacturers and distributors last year, urging them to take precautions and prevent contamination by microorganisms. Also Read | Venezuela archaeologists discover ancient rock art sites from a 'previously unknown' culture Researchers examined 49 tattoo ink samples, out of which nine had bacterial growth. While testing for PMU inks, 17 out of 35 were found to be contaminated. It was also discovered that 35 per cent of the sealed and unopened inks which were tested had both aerobic and anaerobic bacteria contamination. Aerobic bacteria are bacteria which can survive and grow in the presence of oxygen, while anaerobic bacteria can survive even without the presence of oxygen. They can live in the dermal skin layer and injured human tissue. It is not immediately known which brands were included in the study and whether the FDA took any measures against the brands of which products were found to be contaminated. Also Read | Ancient Egyptian writers also hunched over devices and suffered the consequences Researchers claim that the sterilisation process undertaken by brands is either ineffective or their claims are false regarding them being "sterile". Previously, it was believed that tattoo-related infections and complications are caused by allergic and inflammatory reactions due to improper hygiene. However, recent studies have pointed out that contamination of the ink may also be the reason. (With inputs from agencies)

FDA finds contamination in tattoo ink and permanent makeup products of many brands

Here, we bring you the news that is trending across WION's social media platforms: - Did birds evolve from dinosaurs? Fossils of largest feathered dinosaur hint at ancestry - Spain: Olive oil harvest decreases; Is climate change to blame? - NASA observes Mars flare up during epic solar storm - Nearly 60% children suffer from violent methods of upbringing at home, says UN body

Did birds evolve from dinosaurs? | Alzheimer's drug donanemab gets backing from FDA | Trending on WION

On May 9, 1960, the US Food and Drug Administration (FDA) approved the first birth control pill.

Gravitas Recall: US FDA approved the first birth control pill, 64 years ago today

Less than a month ago, Neuralink announced that its brain-computer interface had been approved for human testing. However, Reuters has now reported that the U.S. Food and Drug Administration (FDA) discovered that the company had failed to keep records of animal experiments. The FDA also said that there were some issues with quality control. Investigators found quality control lapses at Neuralink’s animal research facilities in California. However, similar inspections of facilities in Texas found no problems.

Elon Musk's Neuralink brain implant malfunctioned weeks post-operation

Elon Musk's Neuralink brain implant hits a snag

A health alarm was raised across the United States after the Food and Drug Administration (FDA) on Tuesday (April 23) said that they had found fragments of the bird flu virus in a few samples of pasteurised milk in the United States.

A health alarm was raised across the United States after the Food and Drug Administration (FDA) on Tuesday (April 23) said that they had found fragments of the bird flu virus in a few samples of pasteurised milk in the United States. Although the agency has maintained that the milk is safe for consumption, it emphasised that it is still waiting for the results of the test to confirm this. The findings of the FDA emerged less than a month after the H5N1 strain of bird flu was discovered for the first time in dairy cows in several states. Since then, the flu has been detected in herds in eight states. Also Read: Experts flag potential Bird Flu epidemic as '100 times worse than Covid' The FDA has been working to investigate the outbreak with the US Department of Agriculture and the Centres for Disease Control and Prevention. Commercial milk supply is safe, says FDA The FDA said that the fragments of the virus were discovered when the pasteurised milk samples were tested. The testing method used is called PCR testing which looks for bits of genetic material. If the result is positive, that doesn't mean they have found a live, infectious virus. Watch: USDA reveals bird flu updates, Cattle movement implicated in bird flu outbreak “Based on available information, pasteurisation is likely to inactivate the virus, however, the process is not expected to remove the presence of viral particles,” said the agency in a release that it plans to make public on Tuesday. “To date, we have seen nothing that would change our assessment that the commercial milk supply is safe. Results from multiple studies will be made available in the next few days to weeks,” added the agency. Specifically, the FDA is looking at whether bird flu in cow milk is inactivated by pasteurisation. The findings will be available in the “next few days to weeks,” it stated. The FDA in its testing will use egg inoculation tests, which are seen as the gold standard to determine if a sample is infectious. In this test, they inject a chicken egg with a small amount of infected milk and observe if the active virus starts to replicate. (With inputs from agencies)

FDA traces fragments of bird flu virus in pasteurised milk, detailed report awaited

In a breakthrough for abortion rights in the United States two of the biggest Pharmacy chains are set to roll out the abortion pill Mifepristone in the market available on prescription starting next week. In January, the FDA changed regulations to allow retail pharmacies to sell the drug mifepristone. Watch to know more!

US: CVS and Walgreens pharmacies get a nod to dispense Mifepristone

All is not well with Elon Musk's Neurallink the brain chip startup is facing regulatory scrutiny from the US Food and Drug Administration. According to reports the FDA records have revealed issues at Neurallink's California facility related to record-keeping and quality controls for animal experiments.

Neuralink's animal lab concerns raised by FDA

The US Food and Drug Administration issued a warning on Wednesday about smartwatches and rings that make the claim to be able to detect blood sugar levels for medical purposes without piercing the skin. These devices may be harmful and should be avoided.

FDA warns blood sugar can't be measure without needles: Smart watches and rings are all scam

The US Food and Drug Administration has approved the first-ever treatment to treat severe frostbite among adults. The medicine will considerably reduce the risk of amputation sold under the brand name or Lumin. It is expected to be available in the spring of this year.

FDA approves Iloprost: First-ever breakthrough treatment for frostbite

Fda, News on Fda, stories on Fda, articles on Fda, Fda stories at Wion, Fda news, Fda latest news

fda

New drug offers hope for advanced pancreatic cancer

FDA approves new pill that nearly doubles pancreatic cancer survival time

Maharashtra FDA crackdown: Shah Rukh Khan & Ajay Devgn receive FDA notices

Karnataka FDA finds cockroaches and expired food in Vidhan Soudha canteen raid

Maharashtra ramps up food safety raids across state

FDA Commissioner Tukaram Mundhe highlights key food safety concerns on WION

Maharashtra: New FDA chief Tukaram Mundhe conducts mass inspections

Maharashtra: New FDA chief Tukaram Mundhe conducts mass inspections

Maharashtra FDA launches new guidelines: Government to prohibit sale of junk food near schools

FDA suspends food licences of five Mumbai clubs over serious hygiene violations

US drug regulator approves first-of-its-kind anti-obesity pill 'Wegovy'

No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill

FDA Probes Deaths Likely Related To COVID Jab: Plans To Tighten Vaccine Oversight

US government's BIG secret out: FDA kept deadly E. coli outbreak in 15 states hidden. Here's what caused it

No more food safety inspections in US? FDA's new plan unveiled amid massive staff cuts

US FDA approves first new UTI drug in decades

FDA scientists told not to use words ‘women’, ‘disabled’, ‘elderly’; White House calls it ‘error’

Cal Yee products recalled after FDA inspection

FDA expands weight loss drug Zepbound approval to treat sleep apnea

FDA expands weight loss drug Zepbound approval to treat sleep apnea

Musk’s Neuralink announces Blindsight to provide vision to blind, gets FDA's approval

FDA finds contamination in tattoo ink and permanent makeup products of many brands

Did birds evolve from dinosaurs? | Alzheimer's drug donanemab gets backing from FDA | Trending on WION

Gravitas Recall: US FDA approved the first birth control pill, 64 years ago today

Elon Musk's Neuralink brain implant malfunctioned weeks post-operation

Elon Musk's Neuralink brain implant hits a snag